The French Competition Council authorises pharmaceutical laboratories’ practices concerning drugs parallell imports and exports on the basis of both French and EC provisions (Pharma-Lab / GlaxoSmithKline)

Pharma-Lab, Pharmajet, Pharmadex TMC, European Trade Company (ETC) and AD Pharm export drugs bought at the government-fixed price from pharmaceutical laboratories and sell them abroad for a higher price. These companies claimed to suffer from delivery restrictions, discriminatory commercial terms or refusal of sale on the part of the following pharmaceutical laboratories : Glaxo-Wellcome now GlaxoSmithkline (“GSK”), Lilly France, Boehringer Ingelheim, Wyeth Lederlé, Leo France, Ferring, Abbott Medisense France, Novartis Pharma, Pfizer, Merck Sharp et Dohme-Chibret (“MSD”), Norgine

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Gide Loyrette Nouel (Paris)

Quotation

Laura Castex, The French Competition Council authorises pharmaceutical laboratories’ practices concerning drugs parallell imports and exports on the basis of both French and EC provisions (Pharma-Lab / GlaxoSmithKline), 20 December 2005, e-Competitions Bulletin December 2005, Art. N° 449

Visites 16205

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues